Please select from one of the tools below:

Early Melanoma
First Primary
Melanoma Risk
First Primary Melanoma Risk
Sentinel Node
Metastasis Risk
Sentinel Node Metastasis Risk
Subsequent Primary
Melanoma Risk
Subsequent Primary Melanoma Risk
Thin Melanoma
Recurrence Risk
Thin Melanoma Recurrence Risk
Stage II
Survival Prediction
Stage II Survival Prediction
Advanced Melanoma
Outcomes Prediction
Immunotherapy Outcomes Prediction

These prediction tools are intended to guide informed discussions about treatment between clinicians and their patients.

The data that underpin these risk prediction tools are published in peer-reviewed journals (view references.)


• The Australian Medical Research Future Fund and Sydney Health Partners • The Australian National Health and Medical Research Council • The Cameron family for their generous support of clinical research data collection at Melanoma Institute Australia • Colleagues at Melanoma Institute Australia and the Royal Prince Alfred, Westmead and Royal North Shore Hospitals, Sydney • Melanoma Institute Australia‚Äôs generous donors and partners • Cancer Institute New South Wales • The Medical Foundation of The University of Sydney • Colleagues from the University of Texas MD Anderson Cancer Center • Melanoma patients and the public who allowed their data to be used to develop and validate these melanoma risk tools • Researchers and participants from the Australian Melanoma Family Study and GEM study • The University of Sydney • The Sydney Local Health District • New South Wales Health Pathology